Site map Pfizer Sites Contact us Pfizer Global Login
                     
Pfizer South Africa Who we are What we do Well at Pfizer Your health Helping Communities Careers
 

Introduction
What is Overactive Bladder?
What is urinary incontinence?
What causes OAB?
What effect does OAB have on quality of life?
Is OAB associated with other medical problems?
How is OAB diagnosed?
How is OAB treated?
Take control
References
Print this page

References:

    1. Hu T-W, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int 2005; 96(Suppl 1):43-45.
    2. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101:1388-1395.
    3. Abrams P. Urgency: the key to defining the overactive bladder. BJU Int 2005; 96(Suppl 1):1-3.
    4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87:760-766.
    5. McKertich K. Urinary incontinence. Assessment in women: stress, urge or both? Austr Fam Phys 2008; 37(3):112-117.
    6. Ouslander JG. Management of Overactive Bladder. N Engl J Med 2004; 350(8):786-799.
    7. Floridashealth.com. Women’s Health. Your Body. Urinary Incontinence. [Internet]. 2010 [cited 2010 Jun 3]. Available from: http://www.doh.state.fl.us/Family/wh/lifespan/Middleage/urinary.html
    8. Cardozo L. The overactive bladder syndrome: treating patients on an individual basis. BJU Int 2007; 99(Suppl 3):1-7.
    9. Rogers RG. Urinary Stress Incontinence in Women. N Engl J Med 2008; 358(10):1029-1036.
    10. Coyne KS, Margolis MK, Zyczynski T, Elinoff V, Roberts R. Validation of an Overactive Bladder Screener in a Primary Care Patient Population in the United States. Poster presented at the 34th Joint Meeting of the International Continence Society and the International UroGynecological Association; August 23-27, 2004. Paris, France.
    11. Dmochowski RR, Sanders SW, Appell RA, Nitti VW, Davila GW. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int 2005; 96:1049-1054.
    12. Hashim H, Abrams P. How should patients with an overactive bladder manipulate their fluid intake? BJU Int 2008; 102:62-66.
    13. Kincade JE, Dougherty MC, Busby-Whitehead J, Carlson JR, Nix WB, Kelsey DT, et al. Self-Monitoring and Pelvic Floor Muscle Exercises to Treat Urinary Incontinence. Urol Nurs 2005; 25(5):353-363.
    14. Santiagu SK, Arianayagam M, Wang A. Urinary incontinence. Pathophysiology and management outline. Austr Fam Phys 2008; 37(3):106-110.
    15. Herbruck LF. Stress Urinary Incontinence: an Overview of Diagnosis and Treatment Options. Urol Nurs 2008; 28(3):186-198.
    16. Mount Nittany Medical Center. Treating Incontinence in Women: Lifestyle Changes & Kegels. [Internet]. 2010 [cited 2010 Jun 3]. Available from: http://www.mountnittany.org/wellness-library/healthsheets/documents
    17. National Association For Continence. Bladder Diary ("Uro-Log"). [Online]. 2010 [cited 2010 March 31]; Available from: URL:http://www.nafc.org/uploads/pdf/OnlineUroLog.pdf

Brought to you by Pfizer in the interests of healthcare education and awareness

Pfizer Laboratories (Pty) Ltd. Reg. No.: 1954/000781/07. P.O. Box 783720, Sandton 2146. Tel. No.: 0860 PFIZER (734 937)

top